梅花生物(600873) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 6.27 billion, a decrease of 3.36% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 1.02 billion, representing a growth of 35.52% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 42.07% to CNY 904.57 million[4] - Basic and diluted earnings per share rose by 38.46% to CNY 0.36[4] - The weighted average return on equity increased by 1.60 percentage points to 6.78%[4] - The company reported a profit before tax of ¥1,202,262,709.83 for Q1 2025, compared to ¥875,531,219.87 in Q1 2024, marking a growth of 37.1%[21] - Earnings per share for Q1 2025 was ¥0.36, up from ¥0.26 in Q1 2024[21] Cash Flow and Liquidity - The net cash flow from operating activities surged by 1,590.89% to CNY 453.27 million, primarily due to a decrease in raw material prices[4] - In Q1 2025, the company reported a net cash flow from operating activities of ¥453,267,070.69, a significant improvement compared to a net outflow of ¥30,402,361.94 in Q1 2024[22] - The company's cash and cash equivalents decreased to RMB 3,015,835,017.01 from RMB 4,561,056,193.96, representing a decline of about 33.9%[15] - The company’s cash and cash equivalents at the end of Q1 2025 were ¥2,632,431,576.72, a decrease from ¥4,446,176,513.34 at the end of Q1 2024[23] - Total cash inflow from operating activities was ¥6,754,619,422.68, slightly down from ¥6,789,691,782.87 in the same period last year[22] - The total cash outflow for operating activities was ¥6,301,352,351.99, down from ¥6,820,094,144.81 in the same quarter last year[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24.30 billion, up 2.05% from the end of the previous year[4] - The company's total assets amounted to RMB 24,296,858,473.57, an increase from RMB 23,809,558,011.66 at the end of December 2024, reflecting a growth of approximately 2.05%[15] - The company's total liabilities decreased to ¥8,845,396,124.40 in Q1 2025 from ¥9,234,612,710.73 in Q1 2024, reflecting a reduction of 4.22%[18] - Total equity attributable to shareholders increased to ¥15,451,462,349.17 in Q1 2025 from ¥14,574,945,300.93 in Q1 2024, representing a growth of 6.01%[18] Operational Metrics - The decline in revenue was attributed to lower market prices for key products despite an increase in sales volume for certain items[7] - The company's inventory rose to RMB 3,065,170,465.97 from RMB 2,722,279,908.07, marking an increase of around 12.63%[16] - The company's accounts receivable increased to RMB 682,688,208.89 from RMB 587,909,538.21, reflecting a growth of approximately 16.08%[15] - Research and development expenses for Q1 2025 were ¥103,233,375.21, an increase of 13.1% from ¥90,844,311.14 in Q1 2024[20] Shareholder Activities - The company repurchased a total of 35,708,400 shares, which is 1.25% of the total share capital, with a total expenditure of RMB 352,024,400, averaging between RMB 9.10 and RMB 10.68 per share[13] - The employee stock ownership plan involves 290 participants with a total subscription of 225,110,000 shares, indicating strong employee engagement[12] - The company has not reported any changes in the top 10 shareholders or the top 10 unrestricted circulating shareholders due to securities lending activities[10] - The company is committed to adhering to regulatory requirements regarding share repurchase and will continue to disclose relevant information in a timely manner[13]